BioTech Investments on Wall Street – When Does Investing and Profiteering on Wall Street Over Ride The Focus for Creating
Posted May 10 2010 5:45pm
Yes Dendreon is the company that has been all over the news with the vaccine for prostate cancer. As you can see there’s very little income here as they have been operating with money invested and perhaps money gained from the stock market. This company has been on a roller coaster with investors for a couple years now and again the work they are doing and research is profound but what went on in the market is aside from this fact.
The CEO has done well at selling twice when the stock was at a peak and made millions. He sold while the stock was at $51.01 a share and then when the stock dropped, bought back a ton of shares at a price of $4.41 to $9.97 a share. I’m not picking on Dendreon and there are lots of others in this same circle on the market and certainly their contribution with the prostate vaccine is ground setting in being the first of it’s kind, but it just looks like to some there’s more excitement in the share price and in gambling than what their drug and company will be doing?
Again there’s wind up time to begin selling the drug/vaccine and getting facilities ready before even a dollar is seen and the cost and who will be able to afford the drug as well as reimbursements is still out there to be determined yet, but again, is the excitement of the rally on the dollar exceeding the excitement on a contribution to disease and healthcare here? Are we yet still out of touch with everyone maybe headed in the same direction? I didn’t even touch on those in the earlier days hedging against the approval in 2007 and that’s another story of it’s own. BD
SEATTLE, May 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN ) today reported results for the quarter ended March 31, 2010. Revenue for the quarter ended March 31, 2010 was $21,000 compared to $30,000 for the quarter ended March 31, 2009.
The net loss for the quarter ended March 31, 2010 was $125.7 million, or $0.96 per share, compared to $15.4 million, or $0.16 per share for the quarter ended March 31, 2009. The losses for the quarters ended March 31, 2010 and 2009 include a non-cash fair value loss of $68.1 million and gain of $2.4 million, respectively, or $0.52 loss per share and $0.02 gain per share, respectively, associated with the change in the fair value of our warrants. The loss associated with the warrants is a result of the increase in our stock price, while the gain is a result of the decrease in our stock price. These gains or losses do not have any impact on our cash balance, liquidity or cash flows from operations.
As of March 31, 2010, Dendreon had approximately $528 million in cash, cash equivalents, and short-term and long-term investments compared to $606 million as of December 31, 2009.